title: Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats.
abstract: Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) with psychostimulant and neuroprotective effects. Several lines of evidence suggest that treatment with selegiline at doses that exceed levels required for inhibition of MAO can produce distinct pharmacologic effects. The purpose of this study was to evaluate the effects of chronic treatment with high-dose selegiline on extinction responding, cue-induced reinstatement, morphine reinforcement and naloxone-precipitated withdrawal. After pretreatment with noncontingent morphine to establish opiate dependence, rats acquired self-administration of 3.2 mg/kg per injection of morphine under a progressive ratio schedule. Daily treatment with saline or 6.4 mg/kg per day of selegiline was then administered over extinction, reinstatement and re-acquisition of morphine self-administration. To enhance or diminish the potential for psychostimulant effects, selegiline was administered either immediately prior to (pre-session) or 1 h following (post-session) extinction, reinstatement and self-administration sessions. Pre-session selegiline decreased the number of ratios completed on days 2, 3 and 4 of extinction, and decreased morphine self-administration during all four re-acquisition sessions. When administered at the same dose level, post-session selegiline decreased responding on the fourth extinction session, and was ineffective in modifying re-acquisition of self-administration. Selegiline administered by either schedule did not modify cue-induced reinstatement. Daily treatment with 6.4 mg/kg per day of selegiline did not modify self-administration of food under a progressive ratio schedule. Acute treatment with single, 6.4 mg/kg doses of selegiline attenuated naloxone-induced increases in ptosis and global withdrawal score, but did not modify any other sign of withdrawal or global withdrawal score calculated without ratings of ptosis. In conclusion, high-dose selegiline can attenuate extinction responding and morphine-reinforced behavior, and these effects may be mediated by psychostimulant metabolites.
authors.affiliation: Substance Abuse Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA. kenneth.grasing@med.va.gov
authors.forename: K
authors.initials: K
authors.lastname: Grasing
authors.forename: S
authors.initials: S
authors.lastname: He
mesh_terms: D000161:Acoustic Stimulation; D000701:Analgesics, Opioid / Q000009:adverse effects*; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects*; D003463:Cues; D004298:Dopamine / Q000502:physiology; D004435:Eating; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009020:Morphine / Q000009:adverse effects*; D009021:Morphine Dependence / Q000523:psychology*; D009043:Motor Activity / Q000187:drug effects; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010775:Photic Stimulation; D051381:Rats; D017208:Rats, Wistar; D012055:Reinforcement Schedule; D012054:Reinforcement, Psychology; D012642:Selegiline / Q000494:pharmacology*; D012646:Self Administration; D013375:Substance Withdrawal Syndrome / Q000523:psychology*
chemical_list: D000701:Analgesics, Opioid; D008996:Monoamine Oxidase Inhibitors; D009292:Narcotic Antagonists; D012642:Selegiline; D009270:Naloxone; D009020:Morphine; D004298:Dopamine